{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:22:15Z","timestamp":1784694135898,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","award":["CHUSE 24EX237"],"award-info":[{"award-number":["CHUSE 24EX237"]}],"id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10620-025-09210-9","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:32:04Z","timestamp":1753446724000},"page":"3485-3494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn\u2019s Disease"],"prefix":"10.1007","volume":"70","author":[{"given":"N.","family":"Fathallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Draullette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kirchgesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bourrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Haouari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chambenois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Seksik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"de Parades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"9210_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, Gonz\u00e1lez-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"9210_CR2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10151-018-1906-y","volume":"22","author":"D Bouchard","year":"2018","unstructured":"Bouchard D, Pigot F, Staumont G, Siproudhis L, Abramowitz L, Benfredj P, Brochard C, Fathallah N, Faucheron JL, Higuero T, Panis Y, de Parades V, Vinson-Bonnet B, Laharie D. Management of anoperineal lesions in Crohn\u2019s disease: a French National Society of Coloproctology national consensus. Tech Coloproctol 2018;22:905\u2013917. https:\/\/doi.org\/10.1007\/s10151-018-1906-y.","journal-title":"Tech Coloproctol"},{"key":"9210_CR3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999;340:1398\u20131405. https:\/\/doi.org\/10.1056\/NEJM199905063401804.","journal-title":"N Engl J Med"},{"key":"9210_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl 2004;350:876\u2013885. https:\/\/doi.org\/10.1056\/NEJMoa030815.","journal-title":"N Engl"},{"key":"9210_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/14712598.2020.1811849","volume":"21","author":"TL Parigi","year":"2021","unstructured":"Parigi TL, D\u2019Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 2021;21:37\u201346. https:\/\/doi.org\/10.1080\/14712598.2020.1811849.","journal-title":"Expert Opin Biol Ther"},{"key":"9210_CR6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology 2021;160:2340\u20132353. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068.","journal-title":"Gastroenterology"},{"key":"9210_CR7","unstructured":"European Medicines Agency Remsima. European medicines agency, Sept 17, 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima. Accessed on 12 Dec 2021."},{"key":"9210_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, Danese S, K\u0142opocka M, Kierku\u015b J, Kulynych R, Gonciarz M, So\u0142tysiak A, Smoli\u0144ski P, Sre\u0107kovi\u0107 S, Valuyskikh E, Lahat A, Hory\u0144ski M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Yang S, Lee J, Lee J, Kim JM, Park G, Sandborn WJ, Colombel JF. Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY). Gastroenterology 2024;167:919\u2013933. https:\/\/doi.org\/10.1053\/j.gastro.2024.05.006.","journal-title":"Gastroenterology"},{"key":"9210_CR9","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","volume":"21","author":"A Buisson","year":"2023","unstructured":"Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, Laugie M, Manlay L, Mathieu N, Pereira B, Fumery M. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol 2023;21:2338-2346.e3. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.011.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9210_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.16852","volume":"56","author":"X Roblin","year":"2022","unstructured":"Roblin X, Veyrard P, Bastide L, Berger AE, Barrau M, Paucelle AS, Waeckel L, Kwiatek S, Flourie B, Nancey S, Paul S. Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn\u2019s disease. Aliment Pharmacol Ther 2022;56:77\u201383. https:\/\/doi.org\/10.1111\/apt.16852.","journal-title":"Aliment Pharmacol Ther"},{"key":"9210_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","volume":"18","author":"X Roblin","year":"2024","unstructured":"Roblin X, Nancey S, Papamichael K, Duru G, Flamand M, Kwiatek S, Cheifetz A, Fabien N, Barrau M, Paul S. Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease. J Crohns Colitis 2024;18:679\u2013685. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad188.","journal-title":"J Crohns Colitis"},{"key":"9210_CR12","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"AJ Yarur","year":"2017","unstructured":"Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther 2017;45:933\u2013940. https:\/\/doi.org\/10.1111\/apt.13970.","journal-title":"Aliment Pharmacol Ther"},{"key":"9210_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40259-024-00673-2","volume":"38","author":"A Srinivasan","year":"2024","unstructured":"Srinivasan A, van Langenberg D, De Cruz P, Segal J, Vasudevan A, Upton RN. Treatment targets should influence choice of infliximab dose intensification strategy in inflammatory bowel disease: a pharmacokinetic simulation study. BioDrugs 2024;38:691\u2013702. https:\/\/doi.org\/10.1007\/s40259-024-00673-2.","journal-title":"BioDrugs"},{"key":"9210_CR14","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s00330-024-11029-3","volume":"35","author":"KJ Beek","year":"2025","unstructured":"Beek KJ, Mulders LGM, van Rijn KL, Horsthuis K, Tielbeek JAW, Buskens CJ, D\u2019Haens GR, Gecse KB, Stoker J. External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn\u2019s disease. Eur Radiol 2025;35:1428\u20131439. https:\/\/doi.org\/10.1007\/s00330-024-11029-3.","journal-title":"Eur Radiol"},{"key":"9210_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1463-1318.2004.00749.x","volume":"7","author":"C Talbot","year":"2005","unstructured":"Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn\u2019s disease. Colorectal Dis 2005;7:164\u2013168. https:\/\/doi.org\/10.1111\/j.1463-1318.2004.00749.x.","journal-title":"Colorectal Dis"},{"key":"9210_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","volume":"11","author":"G Bouguen","year":"2013","unstructured":"Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Long-term outcome of perianal fistulizing Crohn\u2019s disease treated with infliximab. Clin Gastroenterol Hepatol 2013;11:975\u201381. https:\/\/doi.org\/10.1016\/j.cgh.2012.12.042.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9210_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/codi.12851","volume":"17","author":"A Haennig","year":"2015","unstructured":"Haennig A, Staumont G, Lepage B, Faure P, Alric L, Buscail L, Bournet B, Moreau J. The results of seton drainage combined with anti-TNF\u03b1 therapy for anal fistula in Crohn\u2019s disease. Colorectal Dis 2015;17:311\u2013319. https:\/\/doi.org\/10.1111\/codi.12851.","journal-title":"Colorectal Dis"},{"key":"9210_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","volume":"16","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study. J Crohns Colitis 2022;16:1436\u20131446. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac053.","journal-title":"J Crohns Colitis"},{"key":"9210_CR19","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.3390\/biomedicines10092130","volume":"10","author":"JM Huguet","year":"2022","unstructured":"Huguet JM, Garc\u00eda-Lorenzo V, Mart\u00ed L, Paredes JM, Ram\u00edrez JJ, Pastor M, Ruiz L, Sanahuja A, Timoneda P, Sanch\u00eds L, P\u00e9rez GA, Bosc\u00e1-Watts MM. Subcutaneous infliximab [CT-P13], a True biologic 2.0: real clinical practice multicentre study. Biomedicines 2022;10:2130. https:\/\/doi.org\/10.3390\/biomedicines10092130.","journal-title":"Biomedicines"},{"key":"9210_CR20","doi-asserted-by":"publisher","first-page":"175628481880124","DOI":"10.1177\/1756284818801244","volume":"11","author":"V Bergqvist","year":"2018","unstructured":"Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818801244. https:\/\/doi.org\/10.1177\/1756284818801244.","journal-title":"Therap Adv Gastroenterol"},{"key":"9210_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ibd\/izz271","volume":"26","author":"M Bronswijk","year":"2020","unstructured":"Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M. Evaluating efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar CT-P13: experience from a large tertiary referral center. Inflamm Bowel Dis 2020;26:161. https:\/\/doi.org\/10.1093\/ibd\/izz271.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09210-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09210-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T06:21:37Z","timestamp":1760595697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09210-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["9210"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09210-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6264439\/v1","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethics committee of Saint-Joseph Hospital (IRB 00012157), and all patients signed an information and non-opposition form for the collection of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}